US traders set for heavy losses as Trump abandons copper tariff threat
Prices of the metal traded on US markets hit record highs earlier this month after Trump threatened to impose levies of 50 per cent alongside a list of other goods.
The impact was to see US importers stock up on physical copper in enormous volumes ahead of new levies, sending prices soaring.
It drove US-traded copper prices to a record $5.92/lb a week ago and opened up an enormous premium against prices on the London Metal Exchange and other global metal markets.
But late on Wednesday Trump shocked markets by excluding copper cathodes and input materials such as ores from impending tariffs.
Copper cathodes - high-purity plates of copper used for manufacturing wire, cables, and other components – are what is traded on international metal exchanges.
US prices - Comex copper futures - tumbled by more than 22 per cent to $4.355/lb by early afternoon on Thursday - marking their biggest one-day fall in history.
Dan Smith, managing director at Commodity Market Analytics, told the Reuters news agency the move could be a 'disaster' for some traders.
He said: 'You spent all this money getting stuff across to America and then, it's going to have to sit there, isn't it?'
Steve Clayton, head of equity funds at Hargreaves Lansdown, added: 'The sudden realisation that there was no need for the market to be so dislocated sent US copper prices tumbling back down toward the London benchmark, leaving US buyers nursing heavy losses.'
Meanwhile, benchmark three-month copper on the LME was down 0.7 per cent per cent at $9,631 a ton.
The slide in Comex prices flipped its premium over LME, which had traded at about $3,000 a ton last week, to a $4 discount on Thursday.
London-listed miners suffered, with Antofagasta, Rio Tinto, Glencore and Anglo American falling by 4.2 to 6.4 per cent each.
The most-traded copper contract on the Shanghai Futures Exchange eased 1.3 per cent to 78,040 yuan a ton.
Nikos Tzabouras, senior market analyst at Tradu.com, said: 'The [Trump] administration has left the door open to imposing duties on refined copper in the coming years.
'In addition, the non-ferrous metal continues to benefit from structural demand drivers that could support prices.
'These tailwinds are linked to its usage in semiconductors powering the AI boom, clean energy infrastructure, and military applications amid rising defence budgets.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
a few seconds ago
- Reuters
Swiss stunned by US tariff hike, seek negotiated solution
ZURICH/GENEVA Aug 1 (Reuters) - Swiss manufacturers warned on Friday that tens of thousands of jobs were at risk after U.S. President Donald Trump hit them with one of the highest tariff rates in his global trade reset, even if there was some relief for the key drugs sector. The Swiss government said it would analyse the new situation and decide how to proceed after Trump set a 39% tariff on the export-reliant country - more than double the 15% rate for most European Union imports into the United States. The levy - up from an originally proposed 31% tariff that Swiss officials had described as "incomprehensible" - is a body blow for the small European nation, which counts the U.S. as the top export market for its watches, jewellery and chocolates. "I am stunned. These tariffs are based on no rational basis and are arbitrary," said Stefan Brupbacher, director of manufacturers' association Swissmem. "This decision puts tens of thousands of jobs in the industry at risk." The Swiss Federal Council said it remained in contact with U.S. authorities about the tariffs and "continues to strive for a negotiated solution". The new tariff rate is set to take effect on August 7, and a Swiss source familiar with the matter said the two sides would continue negotiating ahead of that deadline. Swissmechanic, which represents small- and medium-sized companies, said the new rate was excessive and threatened Switzerland's future as a business location. However, there was some respite for the country's pharmaceuticals sector, which includes industry giants Roche (ROG.S), opens new tab and Novartis (NOVN.S), opens new tab, as they were not included in the 39% rate. "Swiss authorities understand that the tariffs should not include the pharmaceuticals sector," a spokesperson for the Swiss Federal Department of Economic Affairs told Reuters. Still, the pharmaceuticals sector is under pressure from Washington to lower prices of drug exports to the United States. "This is a black day for the Swiss economy," said industry association Interpharma. "It is crucial that Switzerland continues negotiations with the U.S. to reduce general tariffs and prevent specific tariffs on pharmaceutical products." Trump's announcement differs significantly from a joint draft statement approved by Switzerland's Federal Council on July 4, following intensive talks between both countries, the federal finance ministry told Reuters in a statement, without giving details. Since then, Swiss officials have been waiting for a sign-off on what was understood to be a preliminary framework for a deal, according to a person familiar with the matter. Swiss Finance Minister Karin Keller-Sutter and Economy Minister Guy Parmelin had visited Washington for talks to press their case: Switzerland is the seventh-largest investor in the United States. The Alpine country sent about 65 billion Swiss francs ($80 billion) of goods to the United States last year, or about one-sixth of its total exports of 394 billion francs. Total trade with the U.S. was 91.9 billion francs, or about 12.7% of all imports and exports, Swiss government data show. Switzerland's trade surplus with the U.S. last year was almost 38.7 billion francs. The U.S. is Switzerland's top foreign watch market, accounting for 16.8% of exports, worth 4.4 billion francs, according to Federation of the Swiss Watch Industry. ($1 = 0.8134 Swiss francs)
Reuters
a few seconds ago
- Reuters
Rupee steadies to cap rough week dominated by Trump's tariff jolt
MUMBAI, Aug 1 (Reuters) - The Indian rupee nudged higher on Friday, supported by likely intervention from the Reserve Bank of India, but still logged its worst weekly drop since late 2022 due to worries over U.S. tariffs and sustained foreign portfolio outflows. The rupee closed at 87.54 against the U.S. dollar on Friday, a tad higher than its close at 87.5950 in the previous session. On the week, the currency declined 1.2%, its worst performance since December 2022. The South-Asian currency fell to 87.74 on Thursday, just shy of its all-time low of 87.95 in February, following President Donald Trump's announcement of a steeper-than-expected 25% tariff on Indian imports. Firm intervention by the central bank on Friday helped the rupee find some footing, but traders and analysts expect a depreciation bias in the near term. Consistent foreign outflows from local stocks alongside elevated corporate dollar demand are likely to keep the local currency under pressure, traders said. Foreign investors net sold $2 billion of Indian equities in July. India's equity benchmarks, the BSE Sensex (.BSESN), opens new tab and Nifty 50 (.NSEI), opens new tab were lower on the day and logged their fifth consecutive weekly fall. Meanwhile, Asian currencies fell after the U.S. imposed sweeping new tariffs on dozens of trading partners. The Korean won led losses with a near 1% fall. The Reserve Bank of India's monetary policy decision and developments related to U.S. trade tariffs will be the key drivers for the rupee next week. "The market now firmly believes that tariffs are transactional rather than ideological," ING said in a note. "Perhaps the biggest risk now is that of secondary sanctions on the likes of China, India and Turkey as Washington tries to turn the screws on Russia and those buying its cheap oil," the brokerage added. The dollar index was up 0.1% at 100.1, as investors await key U.S. labour market data later on Friday to gauge the future path of policy rates in the world's largest economy.
Reuters
a few seconds ago
- Reuters
Kleenex tissue maker Kimberly-Clark's quarterly sales jump on strong demand
Aug 1 (Reuters) - Kimberly-Clark (KMB.O), opens new tab on Friday posted a rise in second-quarter organic sales, led by steady demand for products such as Huggies diapers and Kleenex tissues in domestic and international markets. The Dallas-based firm has broadened its portfolio to offer products from budget to premium price tiers, in an effort to capture demand across income levels and combat competition from rivals such as Procter & Gamble (PG.N), opens new tab. The company has also been streamlining its business to control costs and drive growth in more profitable brands. In June, it struck a $3.4 billion deal to sell a majority stake in its international tissue business to Brazilian pulp maker Suzano ( opens new tab. Organic sales for the quarter ended June 30 was up 3.9%, driven by a 5% growth in overall volumes offsetting a 1.2% decline in prices from last year. Net sales from continuing operations, which exclude the divested unit, came in at $4.16 billion, down 1.6% from last year. It also posted earnings of $1.92 per share. Analysts were expecting $1.67 per share, according to data compiled by LSEG. In April, Kimberly-Clark warned of $300 million in additional costs this year, primarily due to U.S. President Donald Trump's levies on China that have since come down to a 10% level. It now expects adjusted earnings per share attributable for 2025 to grow at a low- to mid-single-digit rate, compared with an earlier forecast for flat-to-positive growth on a constant-currency basis. The profit forecast continues to include the International Family Care and Professional business until the close of the joint venture deal with Suzano in mid-year 2026, Kimberly-Clark said.
